SMA Daily

AveXis Reports Data from Ongoing Phase 1 Trial of Gene Therapy in Spinal Muscular Atrophy Type 1

AveXis Gains Orphan Drug Designation from the European Medicines Agency for Gene Therapy Treatment in Spinal Muscular Atrophy

AveXis Doses First Patient in Gene Transfer Trial for Spinal Muscular Atrophy

AveXis-BioLife Licenses Spinal Muscular Atrophy Gene Therapy Program